Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

License Agreements (Details)			1 Months Ended			3 Months Ended		9 Months Ended
License Agreements (Details)	Sep. 30, 2015 USD ($) shares	May 11, 2015 USD ($) $ / shares shares	Jun. 30, 2019 USD ($)	May 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Sep. 30, 2022 USD ($) item	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) item	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
PD-L1
License Agreements
Non-Refundable milestone payment										$ 4,000,000.0
NeuPharma, Inc
License Agreements
Payment of upfront licensing fees					$ 1,000,000.0
NeuPharma, Inc \| Additional sales milestone
License Agreements
Maximum potential milestone payments						$ 40,000,000.0		$ 40,000,000.0
NeuPharma, Inc \| Clinical and Development Milestone
License Agreements
Maximum potential milestone payments						40,000,000.0		40,000,000.0
NeuPharma, Inc \| Regulatory Approvals To Commercialize The Products
License Agreements
Maximum potential milestone payments						22,500,000		22,500,000
Dana-Farber
License Agreements
Payment of upfront licensing fees					1,000,000.0
Number of shares of common stock granted \| shares	136,830	500,000
Value of common stock shares issued	$ 600,000	$ 32,500
Sale price per share \| $ / shares		$ 0.065
Ownership percentage		5.00%
Cash in exchange for common shares		$ 10,000,000
Maintenance fee								50,000
Dana-Farber \| First commercial sale milestone
License Agreements
Maximum potential milestone payments						21,500,000		21,500,000
Dana-Farber \| Additional sales milestone
License Agreements
Maximum potential milestone payments						60,000,000.0		60,000,000.0
Revenue recognition milestone payments						60,000,000.0		60,000,000.0
Jubilant Biosys Limited
License Agreements
Payment of upfront licensing fees				$ 2,000,000.0
Jubilant Biosys Limited \| Additional sales milestone
License Agreements
Maximum potential milestone payments						89,000,000.0		89,000,000.0
Jubilant Biosys Limited \| Clinical and Development Milestone
License Agreements
Maximum potential milestone payments						89,000,000.0		89,000,000.0
Jubilant Biosys Limited \| Regulatory Approvals To Commercialize The Products
License Agreements
Maximum potential milestone payments						59,500,000		59,500,000
Adimab LLC \| PD-L1
License Agreements
Non-Refundable milestone payment										$ 2,400,000
Adimab LLC \| Clinical and Development Milestone
License Agreements
Maximum potential milestone payments						7,100,000		7,100,000
Adimab LLC \| Regulatory Approvals To Commercialize The Products
License Agreements
Maximum potential milestone payments						4,800,000		4,800,000
Collaboration Agreement With TGTX
License Agreements
Proceeds from upfront fees			$ 1,000,000.0		$ 500,000
Revenue recognition milestone revenue recognized						7,000	$ 1,000	54,000	$ 146,000
Collaboration Agreement With TGTX \| First commercial sale milestone \| PD-L1
License Agreements
Revenue recognition milestone payments						27,600,000		27,600,000
Collaboration Agreement With TGTX \| First commercial sale milestone \| PD-L1 GITR
License Agreements
Revenue recognition milestone payments						21,500,000		21,500,000
Collaboration Agreement With TGTX \| Clinical and Development Milestone \| PD-L1 GITR
License Agreements
Revenue recognition milestone payments						7,000,000.0		7,000,000.0
Collaboration Agreement With TGTX \| Commercial Sales In Specified Territories \| PD-L1
License Agreements
Revenue recognition milestone payments						19,200,000		19,200,000
Collaboration Agreement With TGTX \| Commercial Sales In Specified Territories \| PD-L1 GITR
License Agreements
Revenue recognition milestone payments						14,500,000		14,500,000
Collaboration Agreement With TGTX \| Clinical Development and Regulatory Milestones \| PD-L1
License Agreements
Revenue recognition milestone payments						8,400,000		8,400,000
Sublicense Agreement with TGTX
License Agreements
Proceeds from upfront fees				$ 1,000,000.0
Revenue recognition milestone revenue recognized						$ 41,000	$ 28,000	$ 64,000	$ 106,000
Research and development cost						50.00%		50.00%
Number of clinical development milestones \| item						3		3
Number of licensed products \| item						2		2
Sublicense Agreement with TGTX \| Additional sales milestone
License Agreements
Revenue recognition milestone payments						$ 89,000,000.0		$ 89,000,000.0
Sublicense Agreement with TGTX \| Clinical and Development Milestone
License Agreements
Revenue recognition milestone payments						25,500,000		25,500,000
Sublicense Agreement with TGTX \| Five Regulatory Approvals And First Commercial Sales
License Agreements
Revenue recognition milestone payments						61,700,000		61,700,000
Sublicense Agreement with TGTX \| Clinical Development and Regulatory Milestones
License Agreements
Revenue recognition milestone payments						$ 87,200,000		$ 87,200,000